Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 421 results for blood pressure

  1. Thresholds for interventions in adults aged under 40: In adults aged under 40 with hypertension (with or without type 2 diabetes), what are the appropriate risk and blood pressure thresholds for starting treatment?

    (with or without type 2 diabetes), what are the appropriate risk and blood pressure thresholds for starting treatment? Any explanatory...

  2. Secondary prevention after a myocardial infarction (QS99)

    This quality standard covers preventing further cardiovascular disease after a myocardial infarction (heart attack). It includes assessment and cardiac rehabilitation. It describes high-quality care in priority areas for improvement.

  3. Diabetes: annual care processes (IND10)

    This indicator covers the proportion of adults with diabetes who have received all 9 basic care processes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG13

  4. Alcohol use: brief intervention for people with hypertension (IND197)

    This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 12 months with a FAST score of 3 or more or AUDIT-C score of 5 or more who have received brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM176

  5. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

    Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.

  6. Mepolizumab for treating severe eosinophilic asthma (TA671)

    Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.

  7. Thrombin injections for pseudoaneurysms (HTG33)

    Evidence-based recommendations on thrombin injections for pseudoaneurysms. This involves injecting thrombin into the pseudoaneurysm. The aim is to form a small clot to plug the ‘hole’ in the artery.

  8. Varicose veins in the legs (QS67)

    This quality standard covers diagnosing and managing varicose veins in the legs of adults (aged 18 and over). It includes referral for specialist assessment and treatment options. It describes high-quality care in priority areas for improvement.

  9. Abdominal aortic aneurysm: diagnosis and management (NG156)

    This guideline covers diagnosing and managing abdominal aortic aneurysms. It aims to improve care by helping people who are at risk to get tested, specifying how often to monitor asymptomatic aneurysms, and identifying when aneurysm repair is needed and which procedure will work best.

  10. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

    Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults.

  11. Irreversible electroporation for treating liver metastases (HTG304)

    Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.

  12. Adrenal insufficiency: identification and management (NG243)

    This guideline covers identifying and managing adrenal insufficiency (hypoadrenalism) in babies, children, young people and adults. It aims to improve the treatment of primary, secondary and tertiary adrenal insufficiency, and the prevention and management of adrenal crisis.

  13. Diabetes: ACEi or ARBs (IND134)

    This indicator covers the percentage of patients with diabetes, on the register, with a diagnosis of nephropathy (clinical proteinuria) or micro-albuminuria who are currently treated with an ACE-I (or ARBs). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM95.

  14. Bipolar disorder, psychosis and schizophrenia in children and young people (QS102)

    This quality standard covers recognition, early intervention and long-term management of bipolar disorder, psychosis and schizophrenia in children and young people (under 18). It also includes support for parents and carers. It describes high-quality care in priority areas for improvement.

  15. Psychosis and schizophrenia in children and young people: recognition and management (CG155)

    This guideline covers recognising and managing psychosis and schizophrenia in children and young people. It aims to improve early recognition of psychosis and schizophrenia so that children and young people can be offered the treatment and care they need to live with the condition.